N/A Completed N=33 Randomized Quadruple-blind Basic Science

Effects of Fish Oils on Inflammation and Insulin Resistance

Metabolic Syndrome · Insulin Resistance

Source: ClinicalTrials.gov NCT00579436 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2018

Primary outcomePrimary: Baseline Adipocyte Size — 4958; 4489 square micrometers — p=.05

Summary

The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.

Outcome Measures

Outcome	Result	p-value
PRIMARY Baseline Adipocyte Size	4958; 4489	.05
PRIMARY Adipocyte Size After Fish Oil Treatment	4869; 4051	0.05
SECONDARY Baseline Insulin Resistance	1.8; 1.8	0.5
SECONDARY Insulin Resistance After Fish Oil Regiment	1.7; 1.5	0.5

Eligibility Criteria

Inclusion Criteria

BMI 27-45 kg/m2
age 35-65 years
abnormal carbohydrate metabolism

Exclusion Criteria

triglycerides over 700 mg/dl
renal disease
liver disease
congestive heart failure
history of heart disease or stroke
chronic aspirin or NSAID use (anti-coagulant)
history of a bleeding disorder
use of statins, fibrates, ACE inhibitors, angiotensin II receptor blockers and glucocorticoids
diet heavy in omega-3 fatty acids (salmon, sardines, flaxseeds)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00579436). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.